Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: Relation to cardiovascular dysfunction and severity of disease

Gut

Volumn 52, Issue 10, 2003, Pages 1511-1517

  Henriksen, J H ^a,b   Gotze J P ^c   Fuglsang, S ^b   Christensen, E ^a   Bendtsen, F ^b   Moller S ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BRAIN NATRIURETIC PEPTIDE; PEPTIDE DERIVATIVE; PRO BRAIN NATRIURETIC PEPTIDE; PROTHROMBIN; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; ALBUMIN BLOOD LEVEL; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OXYGEN TENSION; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QT INTERVAL; VENOUS PRESSURE;

ADULT; AGED; CARBON DIOXIDE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; OXYGEN; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS;

EID: 0141757412     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.10.1511     Document Type: Article

References (47)

1. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral artery vasodilatation hypotheses: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
2. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505-19.
3. Naschitz JE, Slobodin G, Lewis RJ, et al. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000;140:111-20.
4. Estruch R, Fernandezsola J, Sacanella E, et al. Relationship between cardiomyopathy and liver disease in chronic alcoholism. Hepatology 1995;22:532-8.
5. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-7.
6. Laffi G, Barletta G, La Villa G, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891-8.
7. Valeriano V, Funaro S, Lionetti R, et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000;95:3200-5.
8. Bernardi M, Calandra S, Colantoni A, et al. QT interval prolongation in cirrhosis: Prevalence, relationship with severity and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
9. Henriksen JH, Fuglsang S, Bendtsen F, et al. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513-20.
10. Ma Z, Lee S. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
11. Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996;110:1191-8.
12. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
13. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000;118:937-44.
14. Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999;29:640-3.
15. LaVilla G, Romanelli RG, Casini Raggi V, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992;16:156-61.
16. Wong F, Siu S, Liu P, et al. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001;101:621-8.
17. Iwau T, Oho K, Nakano R, et al. High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. J Hepatol 2000;32:426-33.
18. Komeichi H, Moreau R, Cailmail S, et al. Blunted natriuresis and abnormal systemic haemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis. J Hepatol 1995;22:319-25.
19. La Villa G, Riccardi D, Lazzeri C, et al. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. Hepatology 1995;22:1745-50.
20. Salo J, Jimenez W, Kuhn M, et al. Urinary excretion of urodilatin in patients with cirrhosis. Hepatology 1996;24:1428-32.
21. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-96.
22. Hughes D, Talwar S, Squire IB, et al. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 1999;96:373-80.
23. Campell DJ, Mitchelhill KI, Schlicht SM, et al. Plasma aminoterminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail 2000;6:130-9.
24. Goetze JP, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest 2001;61(suppl 234):47-51.
25. Henriksen JH, Bendtsen F, Sørensen TIA, et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989;97:1506-13.
26. Møller S, Wiinberg N, Henriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995;22:88-95.
27. Henriksen JH, Fuglsang S, Bendtsen F, et al. Arterial compliance in patients with cirrhosis. Am J Physiol Gastrointest 2001;280:G584-94.
28. 99mTc-diethyl-IDA and indocyanine green as hepatic blood flow indicators in man. J Hepatol 1987;4:66-70.
29. Christensen PK, Gall M-A, Major-Pedersen A, et al. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 2000;60:323-32.
30. Goetze JP, Kastrup J, Pedersen F, et al. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
31. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
32. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.
33. Clerico A, Del Ry S, Maffei S, et al. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40:371-7.
34. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.
35. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
36. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during the evolution of heart failure. Am J Physiol 1998;274:H1684-9.
37. Laffi G, Pinzani M, Meacci E, et al. Renal haemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Gastroenterology 1989;96:167-7.
38. Yan W, Wu F, Morser J, et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000;97:8525-9.
39. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in camparison with those of A-type natriuretic peptide in normal subjects and in patients with heart failure. Circulation 1994;90:195-203.
40. Bendtsen F, Gerbes AL, Henriksen JH. Disposal of atrial natriuretic factor (ANF99-126) in patients with cirrhosis: effect of beta-adrenergic blockade. Scand J Clin Lab Invest 1993;53:547-54.
41. Møller S, Søndergaard L, Møgelvang J, et al. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995;22:472-8.
42. Bomzon A. The effect of bile duct manipulation on cardiovascular responsiveness: in vivo studies. J Pharmacol Taxicol Methods 1998;39:75-9.
43. Gazawi H, Ljubuncic P, Cogan U, et al. The effects of bile acids on beta-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochem Pharmacol 2000;59:1623-8.
44. van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996;24:747-52.
45. Zavecz JH, Bueno O, Maloney RE, et al. Cardiac excitation-contraction coupling in the portal hypertensive rat. Am J Physiol Gastrointest Liver Physiol 2000;279:G28-39.
46. Trevisani F, Merli M, Savelli F, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. J Hepatol 2003;38:461-7.
47. Harcombe AA, Ramsay L, Kenna JG, et al. Circulating antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci 1995;88:263-8.